Download Free The Leukemia Lymphoma Cell Line Factsbook Book in PDF and EPUB Free Download. You can read online The Leukemia Lymphoma Cell Line Factsbook and write the review.

The Leukemia-Lymphoma Cell Line Factsbook represents an essential reference manual for all of the well-characterized leukemia-lymphoma cell lines currently available. It provides the most important facts, using the succinct and user-friendly format that has made the FactsBooks so popular with scientists and clinical researchers. Introductory chapters provide background and perspective for culturing malignant hematopoietic (blood forming) cell lines. These chapters are followed by over 400 comprehensive individual entries. Each cell line entry highlights essential clinical, immunological, genetic, and functional features and includes a comprehensive listing of references. - The full spectrum of malignant cell lines from all hematopoietic cell lineages - Sister cell lines and relevant subclones - Clinical data: patient, diagnosis, treatment status, and specimen source - Authentication of derivation and availability - Immunophenotype - Cytogenetic karyotype - Translocations and fusion genes - Receptor gene rearrangements and genetic alterations - Cell cultures aspects: establishment, medium, doubling time, growth - Cytochemical profile - Cytokine production and response to cytokines - Proto-oncogene and transcription factor expression/alteration - Functional features: differentiation induction, heterotransplantability - Special unique features - Key references
This book represents an essential reference manual for all of the well-characterized leukemia-lymphoma cell lines currently available. It provides the most important facts, using the succinct and user-friendly format that has made the FactsBooks so popular with scientists and clinical researchers. Introductory chapters provide background and perspective for culturing malignant hematopoietic (blood forming) cell lines. These chapters are followed by over 400 comprehensive individual entries. Each cell line entry highlights essential clinical, immunological, genetic, and functional features and includes a comprehensive listing of references. Key Features * the full spectrum of malignant cell lines from all hematopoietic cell lineages * sister cell lines and relevant subclones * clinical data: patient, diagnosis, treatment status, and specimen source * authentication of derivation and availability * immunophenotype * cytogenetic karyotype * translocations and fusion genes * receptor gene rearrangements and genetic alterations * cell cultures aspects: establishment, medium, doubling time, growth * cytochemical profile * cytokine production and response to cytokines * proto-oncogene and transcription factor expression/alteration * functional features: differentiation induction, heterotransplantability * special unique features * key references
The culture of cancer cells is routinely practiced in many academic research centers, biotechnology companies, and hospital laboratories. Cancer Cell Culture: Methods and Protocols describes easy-to-follow methods to guide both novice and more experienced researchers seeking to use new techniques in their laboratories. Our present understanding of the cell and molecular biology of cancer has been derived mainly from the use of cultured cancer cells and we cover a number of the most widely used assays to study function in current use. Part I introduces the basic concept of cancer cell culture and this is followed by a description of the general techniques used in many cell culture facilities. The importance of cell line characterization is now widely recognized and methods to characterize and authenticate cell lines are described in Part II. Part III covers the isolation and development of specific cancer cell types and provides valuable tips for those wishing to derive new cell line models. A wide range of procedures encompassing many of the key functional features of cancer cells are described in Part IV including assays to evaluate clonogenicity, cell proliferation, apoptosis, adhesion, migration, invasion, senescence, angiogenesis, and cell cycle parameters. Methods to modify cancer cells are described in Part V, including protocols for transfection, development of drug-resistance, immortalization, and transfer in vivo. In Part VI methods of coculture of different cell types and contamination of cell lines are covered.
This book describes all human leukemia-lymphoma cell lines that have been established and that grow continuously under standardised in vitro conditions. These lines are derived from cells belonging to all the major hematopoietic cell lineages, i.e. B- and T-lymphocytes, natural killer cells, granulocytic cells and megakaryocytic cells. The clinical data, the culture conditions and the major phenotypic features of the cell lines are described with citations. This book is the first book describing human leukemia-lymphoma cell lines and will be of interest to scientists involved in the areas of hematology, oncology, immunology, molecular biology and cytogenetics. Cancer Cell Lines, Volumes 1-3: These 3 volumes provide a comprehensive text on the culture of established cell lines from every type of human cancer. The volumes provide a basic manual and reference resource for every cancer research scientist using human cancer cells.
Interleukins in Cancer Biology responds to the growing need for credible and up-to-date information about the impact of interleukins on occurrence, development and progression of cancer. It provides reliable information about all known interleukins (38), describes recent discoveries in the field, and moreover, suggests further directions of research on the most promising aspects of this topic. The structure and presentation of the work is very understandable and clear with attention to detail maintained throughout. There are multiple illustrations throughout to help in comprehending and remembering the most important facts. . - Summarizes and discusses existing facts on the impact of all known interleukins in occurrence, development, and progression of cancer - Categorizes and clarifies all interleukins based on their role in cancer - Contains comprehensive and exhaustive information on each molecule
The American Anti-Vivisection Society (AAVS) petitioned the National Institutes of Health (NIH) on April 23, 1997, to prohibit the use of animals in the production of mAb. On September 18, 1997, NIH declined to prohibit the use of mice in mAb production, stating that "the ascites method of mAb production is scientifically appropriate for some research projects and cannot be replaced." On March 26, 1998, AAVS submitted a second petition, stating that "NIH failed to provide valid scientific reasons for not supporting a proposed ban." The office of the NIH director asked the National Research Council to conduct a study of methods of producing mAb. In response to that request, the Research Council appointed the Committee on Methods of Producing Monoclonal Antibodies, to act on behalf of the Institute for Laboratory Animal Research of the Commission on Life Sciences, to conduct the study. The 11 expert members of the committee had extensive experience in biomedical research, laboratory animal medicine, animal welfare, pain research, and patient advocacy (Appendix B). The committee was asked to determine whether there was a scientific necessity for the mouse ascites method; if so, whether the method caused pain or distress; and, if so, what could be done to minimize the pain or distress. The committee was also asked to comment on available in vitro methods; to suggest what acceptable scientific rationale, if any, there was for using the mouse ascites method; and to identify regulatory requirements for the continued use of the mouse ascites method. The committee held an open data-gathering meeting during which its members summarized data bearing on those questions. A 1-day workshop (Appendix A) was attended by 34 participants, 14 of whom made formal presentations. A second meeting was held to finalize the report. The present report was written on the basis of information in the literature and information presented at the meeting and the workshop.
Though overall cancer incidence and mortality have continued to decline in recent years, cancer continues to devastate the lives of far too many Americans. In 2009 alone, 1.5 million American men, women, and children were diagnosed with cancer, and 562,000 died from the disease. There is a growing body of evidence linking environmental exposures to cancer. The Pres. Cancer Panel dedicated its 2008¿2009 activities to examining the impact of environmental factors on cancer risk. The Panel considered industrial, occupational, and agricultural exposures as well as exposures related to medical practice, military activities, modern lifestyles, and natural sources. This report presents the Panel¿s recommend. to mitigate or eliminate these barriers. Illus.
The last ten years have seen the publication of a vast amount of data regarding cellular resistance to drugs in cancer cells. Recent studies have demonstrated that drug resistance assays appear to be predictive of clinical response and suggest that clinicians should now be considering the potential applications of these assays in the treatment of patients with hematological neoplasms. This collection of papers from the International Symposium on the Clinical Value of Drug Resistance Assays in Leukemia and Lymphoma, Amsterdam, 1992, provides a state-of-the-art discussion on drug resistance assays and their role in the design and individualization of treatment protocols.
The Social Security Administration (SSA) administers two programs that provide benefits based on disability: the Social Security Disability Insurance (SSDI) program and the Supplemental Security Income (SSI) program. This report analyzes health care utilizations as they relate to impairment severity and SSA's definition of disability. Health Care Utilization as a Proxy in Disability Determination identifies types of utilizations that might be good proxies for "listing-level" severity; that is, what represents an impairment, or combination of impairments, that are severe enough to prevent a person from doing any gainful activity, regardless of age, education, or work experience.
The fourth edition of The Cytokine Handbook provides an encyclopedic coverage of the molecules that induce and regulate immune responses. Expanded to two volumes, the scope of the book has been broadened to include a major emphasis on the clinical applications of cytokines. The early chapters discuss individual cytokines, chemokines and receptors. Additional chapters discuss the clinical implications and applications of cytokines, including cytokine gene transfer, antisense therapy and assay systems.